Announced
Financials
Sources
Tags
Domestic
Majority
Merger
Pending
Acquisition
biotechnology
United States
Biotechnology
Single Bidder
Friendly
GPCR-targeted therapeutic proteins development
Private
Synopsis
AVROBIO, a biotechnology research, agreed to merge with Tectonic Therapeutic, a pre-clinical stage biotechnology company. Financial terms were not disclosed. “We are delighted to merge with AVROBIO at this important time for Tectonic. We are grateful to our investors for their commitment to our mission and to advancing our pipeline of uniquely differentiated molecules. Using biologics to unlock the therapeutic utility of targeting GPCRs which are not optimally drugged by small molecules could result in important advances for patients. GPCRs are central to human biology and are the target of more than 30% of all currently approved drugs. However, many GPCRs remain unexplored and have proven to be challenging targets for drug development. Our GEODeTM platform makes it possible to discover a broad pipeline of biologics addressing some of the most challenging receptors in the class. This transaction enhances our ability to execute on an efficient plan to advance our clinical-stage and potential best-in-class Fc-relaxin fusion protein, TX45, as well as additional assets in our pipeline. We anticipate multiple clinical catalysts over the next three years,” Alise Reicin, Tectonic Therapeutic CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.